Concurrent Investment Advisors LLC Grows Position in Merck & Co., Inc. $MRK

robot
Abstract generation in progress

Concurrent Investment Advisors LLC significantly increased its stake in Merck & Co., Inc. (MRK) by 147.1% in Q4, acquiring an additional 138,990 shares. This move is part of a broader trend of institutional investors boosting their holdings, now accounting for 76.07% ownership of the company. Despite mixed analyst sentiment and some negative news regarding Gardasil sales and Q1 earnings expectations, Merck shows promise with new strategic partnerships, FDA approvals, and a consensus “Moderate Buy” rating with a $128.47 price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin